Literature DB >> 16206362

Minimal disease activity for rheumatoid arthritis: a preliminary definition.

George A Wells1, Maarten Boers, Beverley Shea, Peter M Brooks, Lee S Simon, C Vibeke Strand, Daniel Aletaha, Jennifer J Anderson, Claire Bombardier, Maxime Dougados, Paul Emery, David T Felson, Jaap Fransen, Dan E Furst, Johanna M W Hazes, Kent R Johnson, John R Kirwan, Robert B M Landewé, Marissa N D Lassere, Kaleb Michaud, Maria Suarez-Almazor, Alan J Silman, Josef S Smolen, Desiree M F M Van der Heijde, Piet L C M van Riel, Fred Wolfe, Peter S Tugwell.   

Abstract

Agreement on response criteria in rheumatoid arthritis (RA) has allowed better standardization and interpretation of clinical trial reports. With recent advances in therapy, the proportion of patients achieving a satisfactory state of minimal disease activity (MDA) is becoming a more important measure with which to compare different treatment strategies. The threshold for MDA is between high disease activity and remission and, by definition, anyone in remission will also be in MDA. True remission is still rare in RA; in addition, the American College of Rheumatology definition is difficult to apply in the context of trials. Participants at OMERACT 6 in 2002 agreed on a conceptual definition of minimal disease activity (MDA): "that state of disease activity deemed a useful target of treatment by both the patient and the physician, given current treatment possibilities and limitations." To prepare for a preliminary operational definition of MDA for use in clinical trials, we asked rheumatologists to assess 60 patient profiles describing real RA patients seen in routine clinical practice. Based on their responses, several candidate definitions for MDA were designed and discussed at the OMERACT 7 in 2004. Feedback from participants and additional on-site analyses in a cross-sectional database allowed the formulation of 2 preliminary, equivalent definitions of MDA: one based on the Disease Activity Score 28 (DAS28) index, and one based on meeting cutpoints in 5 out the 7 WHO/ILAR core set measures. Researchers applying these definitions first need to choose whether to use the DAS28 or the core set definition, because although each selects a similar proportion in a population, these are not always the same patients. In both MDA definitions, an initial decision node places all patients in MDA who have a tender joint count of 0 and a swollen joint count of 0, and an erythrocyte sedimentation rate (ESR) no greater than 10 mm. If this condition is not met: * The DAS28 definition places patients in MDA when DAS28 < or = 2.85; * The core set definition places patients in MDA when they meet 5 of 7 criteria: (1) Pain (0-10) < or = 2; (2) Swollen joint count (0-28) < or = 1; (3) Tender joint count (0-28) < or = 1; (4) Health Assessment Questionnaire (HAQ, 0-3) < or = 0.5; (5) Physician global assessment of disease activity (0-10) < or = 1.5; (6) Patient global assessment of disease activity (0-10) < or = 2; (7) ESR < or = 20. This set of 2 definitions gained approval of 73% of the attendees. These (and other) definitions will now be subject to further validation in other databases.

Entities:  

Mesh:

Year:  2005        PMID: 16206362

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  45 in total

Review 1.  [Sonography of synovial and erosive inflammatory changes].

Authors:  A S Klauser; B Moriggl; C Duftner; V Smekal; L Pallwein; E Mur; M Schirmer
Journal:  Radiologe       Date:  2006-05       Impact factor: 0.635

2.  Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?

Authors:  Nasim Ahmed Khan; Horace Jack Spencer; Essam Ahmed Abda; Rieke Alten; Christof Pohl; Codrina Ancuta; Massimiliano Cazzato; Pál Géher; Laure Gossec; Dan Henrohn; Merete Lund Hetland; Nevsun Inanc; Johannes Wg Jacobs; Eduardo Kerzberg; Maria Majdan; Omondi Oyoo; Ruben A Peredo-Wende; Zahraa Ibrahim Selim; Fotini Nikolaos Skopouli; Alberto Sulli; Kim Hørslev-Petersen; Peter C Taylor; Tuulikki Sokka
Journal:  Ann Rheum Dis       Date:  2012-04-24       Impact factor: 19.103

3.  Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis.

Authors:  Anthony Russell; Ariel Beresniak; Louis Bessette; Boulos Haraoui; Proton Rahman; Carter Thorne; Ross Maclean; Danielle Dupont
Journal:  Clin Rheumatol       Date:  2008-12-17       Impact factor: 2.980

Review 4.  Treat to target in psoriatic arthritis-evidence, target, research agenda.

Authors:  Laura C Coates; Philip S Helliwell
Journal:  Curr Rheumatol Rep       Date:  2015-06       Impact factor: 4.592

5.  The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease.

Authors:  Elena Myasoedova; Arun Chandran; Birkan Ilhan; Brittny T Major; C John Michet; Eric L Matteson; Cynthia S Crowson
Journal:  Ann Rheum Dis       Date:  2015-01-30       Impact factor: 19.103

Review 6.  2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Authors:  Jasvinder A Singh; Daniel E Furst; Aseem Bharat; Jeffrey R Curtis; Arthur F Kavanaugh; Joel M Kremer; Larry W Moreland; James O'Dell; Kevin L Winthrop; Timothy Beukelman; S Louis Bridges; W Winn Chatham; Harold E Paulus; Maria Suarez-Almazor; Claire Bombardier; Maxime Dougados; Dinesh Khanna; Charles M King; Amye L Leong; Eric L Matteson; John T Schousboe; Eileen Moynihan; Karen S Kolba; Archana Jain; Elizabeth R Volkmann; Harsh Agrawal; Sangmee Bae; Amy S Mudano; Nivedita M Patkar; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

7.  Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders.

Authors:  Florence Tubach; Philippe Ravaud; Dorcas Beaton; Maarten Boers; Claire Bombardier; David T Felson; Desireé van der Heijde; George Wells; Maxime Dougados
Journal:  J Rheumatol       Date:  2007-05       Impact factor: 4.666

Review 8.  Patient-reported outcomes in core domain sets for rheumatic diseases.

Authors:  Lilian H D van Tuyl; Maarten Boers
Journal:  Nat Rev Rheumatol       Date:  2015-09-01       Impact factor: 20.543

Review 9.  Outcome measures in inflammatory rheumatic diseases.

Authors:  Jaap Fransen; Piet L C M van Riel
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

10.  Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients.

Authors:  Michel de Bandt; Bruno Fautrel; Jean Francis Maillefert; Jean Marie Berthelot; Bernard Combe; René-Marc Flipo; Frédéric Lioté; Olivier Meyer; Alain Saraux; Daniel Wendling; Xavier Le Loët; Francis Guillemin
Journal:  Arthritis Res Ther       Date:  2009-10-23       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.